Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan [Yahoo! Finance]
Coherus BioSciences, Inc. (CHRS)
Last coherus biosciences, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.coherus.com
Company Research
Source: Yahoo! Finance
REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced it entered into a combined term loan and product royalty financing agreement with Barings that has allowed Coherus to fully pay off the remaining $75 million of its Pharmakon Advisors term loan. This further reduces the Company's term loan debt by approximately half, with an extended loan maturity date of May 2029. “This debt and royalty financing arrangement fully repays the $75 million remaining on our prior $250 million term loan that was due in October 2025,” said Denny Lanfear, Chief Executive Officer of Coherus. “This transaction improves our capital structure, moves the maturity date to a point more consistent with our development horizon, setting us on the course of long-term, sustainable growth as a focused oncology company.” Under the terms of the royalty monetization facility, Coherus received $37.5 million in return for a certain net sales royalty
Show less
Read more
Impact Snapshot
Event Time:
CHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CHRS alerts
High impacting Coherus BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
CHRS
News
- Coherus BioSciences, Inc. (NASDAQ: CHRS) had its price target lowered by analysts at Truist Financial Co. from $8.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Coherus BioSciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Coherus BioSciences, Inc. (NASDAQ: CHRS) had its price target raised by analysts at HC Wainwright from $11.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
CHRS
Earnings
- 5/9/24 - Miss
CHRS
Analyst Actions
- 3/18/24 - HC Wainwright
CHRS
Sec Filings
- 5/13/24 - Form DEFA14A
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- CHRS's page on the SEC website